In vitro and in vivo evaluation of glibenclamide in solid dispersion systems

Drug Development and Industrial Pharmacy

Volumn 30, Issue 6, 2004, Pages 601-607

  Tashtoush, Bassam M ^a   Al Qashi, Zubaida S ^a   Najib, Naji M ^a,b  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b International Pharmaceutical Research Center Amman   (Jordan)

Author keywords

Gelucire ; Glibenclamide; In vitro dissolution; In vivo bioavailability; Polyethylene glycol 6000 (PEG 6000); Solid dispersion

Indexed keywords

GELUCIRE; GLIBENCLAMIDE; MACROGOL 6000;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; TABLET DISINTEGRATION;

ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CAPSULES; CROSS-OVER STUDIES; EXCIPIENTS; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; MALE; PILOT PROJECTS; POLYETHYLENE GLYCOLS; SOLUBILITY; SOLVENTS; TABLETS;

EID: 3142754096     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120037491     Document Type: Article

References (26)

1. Davis, S.N.; Granner, D.K. Insulin, oral hypoglycemic agents and the pharmacology of endocrine pancreas. In The Pharmacological Basis of Therapeutics, 9th Ed.; Gilman, A.G., Ed.; McGraw-Hill: New York, 1996; 1487-1518.
2. Drug Information for Health Care Professional; USP DI. 1999; Vol. I.
3. Chiou, W.L.; Riegelman, S. Increased dissolution rates of water-insoluble cardiac glycosides and steroids via solid dispersions in polyethylene glycol 6000. J. Pharm. Sci. 1971, 60 (10), 1569-1571.
4. Betageri, G.V.; Dipali, S.R. Preparation and in vitro dissolution profiles of tolazamide-polyethylene glycol solid dispersion. Drug Dev. Ind. Pharm. 1995, 21 (11), 1347-1352.
5. Save, T.; Venkitachalam, P. Studies on solid dispersions of nifedipine. Drug Dev. Ind. Pharm. 1992, 18, 1663-1679.
6. Fernandez, J.; Vila-Jato, J.L.; Banco, J.; Ford, J.L. Some properties of diazepam-polyethylene glycol solid dispersion and their modification in the presence of stearic acid or polysorbate 80. Drug Dev. Ind. Pharm. 1989, 15, 2491-2513.
7. Fernanadez, M.; Rodriguez, I.C.; Margarit, M.V.; Cerezo, A. Characterization of solid dispersion of piroxicam/polyethylene glycol 4000. Int. J. Pharm. 1992, 84, 197-202.
8. Araias, M.J.; Gines, J.M.; Moyano, J.R.; Martinez, J.I.; Rabasco, A.M. Influence of the preparation method of solid dispersions on their dissolution rate: study of trimetrene-D-mannitol system. Int. J. Pharm. 1995, 123, 25-31.
9. Dordunoo, S.K.; Ford, J.L.; Rubinstein, M.H. Preformulation studies on solid dispersions containing traimterene or temazepam in polyethylene glycols or gelucire 44/14 for liquid filling of hard gelatine capsules. Drug Dev. Ind. Pharm. 1991, 17, 1685-1713.
10. Gattafosse Technical Dossier. Gelucire Pharmaceutical Excipients for Oral Semisolid Formulation.
11. Sheen, P.C.; Kim, E.I.; Petillo, J.J.; Serajuddin, A.T.M. Bioavailability of poorly water-soluble drug for tablet and solid dispersion in human. J. Pharm. Sci. 1991, 80 (7), 712-714.
12. Reynolds, J.E. Martindale: The Extra Pharmacopoeia, 30th Ed.; The Pharmaceutical Press: London, 1993;1384.
13. Rabasco, A.M.; Gines, J.M.; Fernandez, A.; Hogado, M.A. Dissolution rate of diazepam from PEG 6000 solid dispersion. Int. J. Pharm. 1991, 67, 201-205.
14. Sheu, M.-T.; Yeh, C.-M.; Sokoloski, T.D. Characterization and dissolution of fenofibrate solid dispersion systems. Int. J. Pharm. 1994, 103, 137-246.
15. Jachowics, R.; Nurberg, E.; Hoppe, R. Solid dispersion of oxazepam. Int. J. Pharm. 1994, 99, 321-325.
16. Dressman, J.B.; Amidon, G.L.; Reppas, C.; Shan, V.P. Dissolution testing as aprognostic tool for oral drug absorption; Immediate release dosage forms. Pharm. Res. 1998, 15 (1), 11-22, review.
17. Qureshi, S.; McGilveray, I. Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product. Eur. J. Pharm. Sci. 1999, 7, 249-258.
18. Blume, H.; Ali, S.; Siewert, M. Pharmaceutical quality of glibenclamide products: a multinational postmarketing comparative study. Drug Dev. Ind. Pharm. 1993, 19 (20), 2713-2741.
19. El-sayed, Y.M.; suleiman, M.S.; Hasam, M.M.; Abdel-Hamid, M.E.; Najib, N.M.; Sallem, E.S.; Subair, M.S. Comparison of the pharamacokinetics and pharmacodynamics of two commercial products containing glibenclamide. Int. J. Clin. Pharmacol. Therm. Toxicol. 1989, 27 (11), 551-557.
20. Al-Kamis, K.; El-sayed, Y.; Al-Rashood, K.; Al-Yamani, M. High performance liquid chromatographic method for determination of glibenclamide in human plasma. Anal. lett. 1994, 27 (7), 1277-1293.
21. Chiou, W.; Riegelman, S. Pharmaceutical application of solid dispersion systems. J. Pharm. Sci. 1971, 60 (9), 1281-1302.
22. Neugebauer, G.; Betzien, G.; Hrstka, V.; kauhmann, B.; Von mdlendorff, E.; Abshagen, U. Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglycon® N). Int. J. Clin. Pharmacol. Ther. Toxicol. 1985, 23 (9), 453-460.
23. Shaheen, O.; Othman; Sadeq; Jalal, I.; Awidi, A.; Al-Turk, W. Comparison of pharmacokinetics and pharmacodynamics of a conventional and a new rapidly dissolving glibenclamide preparation. Int. J. Pharm. 1987, 38, 123-131.
24. Marchetti, P.; Giannarelli, R.; Carlo, A.; Navalesi, R. Pharamacokinetics optimization of oral hypoglycemic therapy. Clin. Pharmacokinet. 1991, 21 (4), 308-317.
25. Podczeck, F. Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT). Int. J. Pharm. 1993, 97, 93-100.
26. Santosh, J.V. Dissolution testing and assessment of bioavailability/ bioequivalence. In Pharmaceutical Dissolution Testing; Banker, U.V., Ed.; Marcel Dekker, Inc.: New York, 1992; 391-411.